These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34053399)

  • 41. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stepwise two-stage sample size adaptation.
    Wan H; Ellenberg SS; Anderson KM
    Stat Med; 2015 Jan; 34(1):27-38. PubMed ID: 25252082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exact Unconditional Tests for Dichotomous Data When Comparing Multiple Treatments With a Single Control.
    Shan G; Dodge-Francis C; Wilding GE
    Ther Innov Regul Sci; 2020 Mar; 54(2):411-417. PubMed ID: 32072588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.
    Kidwell KM; Roychoudhury S; Wendelberger B; Scott J; Moroz T; Yin S; Majumder M; Zhong J; Huml RA; Miller V
    Orphanet J Rare Dis; 2022 May; 17(1):186. PubMed ID: 35526036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blinded sample size recalculation in clinical trials incorporating historical data.
    Hees K; Kieser M
    Contemp Clin Trials; 2017 Dec; 63():2-7. PubMed ID: 28735110
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection.
    Neal D; Casella G; Yang MC; Wu SS
    Stat Med; 2011 Oct; 30(23):2804-14. PubMed ID: 21823142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interval estimation in multi-stage drop-the-losers designs.
    Lu X; He Y; Wu SS
    Stat Methods Med Res; 2018 Jan; 27(1):221-233. PubMed ID: 26980742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
    Kunzmann K; Kieser M
    Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimized adaptive enrichment designs for three-arm trials: learning which subpopulations benefit from different treatments.
    Steingrimsson JA; Betz J; Qian T; Rosenblum M
    Biostatistics; 2021 Apr; 22(2):283-297. PubMed ID: 31420983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blinded sample size recalculation in clinical trials with binary composite endpoints.
    Sander A; Rauch G; Kieser M
    J Biopharm Stat; 2017; 27(4):705-715. PubMed ID: 27295402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
    Jahn-Eimermacher A; Hommel G
    Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential designs with small samples: Evaluation and recommendations for normal responses.
    Nikolakopoulos S; Roes KC; van der Tweel I
    Stat Methods Med Res; 2018 Apr; 27(4):1115-1127. PubMed ID: 27342574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2017 Feb; 17(1):22. PubMed ID: 28166741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A proof-of-concept-to-confirmatory multiple adaptation design in the development of an anti-viral treatment.
    Fan XF; Gallo P; Su G; Menton R; Segal F
    Stat Methods Med Res; 2019 Dec; 28(12):3491-3501. PubMed ID: 30375280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.